ArticleWorld journal of gastroenterology2025
Predictive value of core-fucosylated low-molecular-weight kininogen levels in patients with liver fibrosis: A prospective study.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCore-fucosylated low-molecular-weight kininogen (LMWK-Fc) levels are significantly elevated in patients with liver fibrosis and cirrhosis.
aimTo assess the value of LMWK-Fc as a diagnostic biomarker for liver fibrosis.
methodsOur study included 132 healthy people and 132 patients with liver fibrosis. The LMWK-Fc level was measured based on the principle of chemiluminescence. Fibrosis stage and inflammatory activity were assessed by liver biopsy. Comparative analysis between groups and receiver operating characteristic curve analysis were performed.
resultsLMWK-Fc had an area under the curve of 0.871, which indicates a good level of performance in distinguishing between patients with and without fibrosis. Furthermore, the LMWK-Fc level had a certain correlation with the liver stiffness value, which reached 0.5789.
conclusionLMWK-Fc could be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.